Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis

Only biologic approved in the European Union for patients aged 12 and above with moderate-to-severe atopic dermatitis Approval is based on Phase 3 trial results showing Dupixent significantly improved disease extent and severity, skin clearance, and itc... Biopharmaceuticals, Dermatology, Regulatory Regeneron Pharmaceuticals, Sanofi, Dupixent, dupilumab, atopic dermatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news